PAVmed Chairman & CEO Lishan Aklog, M.D. named Top 50 Healthcare Technology CEO by Healthcare Technology Report
15 April 2021 - 3:30PM
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”
or “PAVmed”), a commercial-stage, multi-product medical device
company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman
and Chief Executive Officer and Executive Chairman of its
majority-owned subsidiary, Lucid Diagnostics Inc., was selected as
one of the Top 50 Healthcare Technology CEOs of 2021 by Healthcare
Technology Report.
“I am humbled to be named among such a prominent
and accomplished group of industry leaders,” said Dr. Aklog. “This
honor is first and foremost a recognition of PAVmed’s incredible
team, who are working tirelessly, along with our world-class
partners and advisors, to advance and commercialize groundbreaking
innovations to improve patient care and save lives.”
Healthcare Technology Report described this
year’s awardees as representing “some of the most accomplished
executives in healthcare technology” whose “leadership has been
critical in developing industry leading medical devices, next
generation software platforms, cutting-edge drugs and therapeutics,
and advanced diagnostics, among other technologies” and who have
made “significant contributions to society at large.” Its editors
evaluated hundreds of CEOs in the fields of medical devices,
biotech, healthcare analytics, healthcare software and other
related areas. Nominees were assessed across several key areas
including breadth of leadership experience in the healthcare
technology industry, level of expertise and domain knowledge in
their particular field, depth of their executive team’s experience
and consistency of organizational performance. Notably, in addition
to overseeing their companies’ efforts from the C-suite, many of
these leaders were also, as Dr. Aklog is, founders or co-founders
of their organizations, recognizing unique opportunities for
transformation and growth within their areas of expertise. Dr.
Aklog joins the list alongside CEOs of leading medical device and
diagnostic technology companies including Medtronic, Thermo Fisher,
BD, Edwards Lifesciences, DexCom, Ortho Clinical Diagnostic and
Guardant Health.
About Lishan Aklog, M.D.
Dr. Lishan Aklog serves as Chairman & CEO of
PAVmed, Inc. (Nasdaq: PAVM, PAVMZ) which he and his partners
co-founded with a vision to build a high-growth multi-product
medical technology company advancing and commercializing a
portfolio of groundbreaking products, starting with their own
innovations and expanded through acquisition or licensing of
technologies from academic medical centers or clinician innovators.
Dr. Aklog serves concurrently as Executive Chairman of PAVmed’s
major subsidiary, Lucid Diagnostics Inc., which markets the only
commercially available tools for early precancer detection to
prevent esophageal cancer in patients with chronic heartburn. He
also serves on the board of directors of two life sciences
companies, and the leading medical technology trade association,
AdvaMed. He and his partners previously co-founded Pavilion
Holdings Group, which created four medical device companies,
including Vortex Medical, which developed and commercialized his
life-saving invention AngioVac® prior to its acquisition by
Angiodynamics (Nasdaq: ANGO). Before he transitioned to a career as
an entrepreneur and executive in the life sciences industry, Dr.
Aklog had a distinguished academic and clinical career as a
technological innovator in cardiac surgery, serving on the faculty
of leading institutions, including Harvard Medical School and Mount
Sinai School of Medicine. He received his A.B. degree from Harvard
College, graduating Phi Beta Kappa and magna cum laude in Physics
and his M.D. degree, cum laude, from Harvard Medical School. He
completed his surgical training at Harvard’s Brigham and Women’s
Hospital and Boston Children’s Hospital, Harefield Hospital, London
and L’Hôpital Broussais, Paris. Dr. Aklog, who fled political
violence in Ethiopia as a young teenager, has been active in
philanthropic organizations, including as a member of the
international board of directors of Human Rights Watch.
About PAVmed
PAVmed Inc. is a multi-product, commercial-stage
medical device company employing a unique business model designed
to advance innovative products to commercialization rapidly and
with less capital than the typical medical device company. This
proprietary model enables PAVmed to pursue an expanding pipeline
strategy with a view to enhancing and accelerating value creation
while seeking to further expand its pipeline through relationships
with its network of clinician innovators at leading academic
centers. PAVmed’s diversified product pipeline addresses unmet
clinical needs encompassing a broad spectrum of clinical areas with
attractive regulatory pathways and market opportunities. Its four
operating divisions include GI Health (EsoGuard® Esophageal DNA
Test, EsoCheck® Esophageal Cell Collection Device, and EsoCure™
Esophageal Ablation Device with Caldus™ Technology), Minimally
Invasive Interventions (CarpX® Minimally Invasive Device for Carpal
Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus
Vascular Access Device and NextFlo™ Highly Accurate Infusion
Platform Technology), and Emerging Innovations (non-invasive
laser-based glucose monitoring, pediatric ear tubes, and mechanical
circulatory support). For more information, please
visit www.pavmed.com, follow us on Twitter, connect with us on
LinkedIn, and watch our videos on YouTube. For more information on
our majority owned subsidiary, Lucid Diagnostics Inc., please visit
www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on
LinkedIn. For detailed information on EsoGuard, please visit
www.EsoGuard.com and follow us on Twitter, Facebook and
Instagram.
Forward-Looking Statements
This press release includes forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements, based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock, Series W Warrants and Series Z
Warrants; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time
required advance PAVmed’s products to regulatory submission;
whether regulatory authorities will be satisfied with the design of
and results from PAVmed’s preclinical studies; whether and when
PAVmed’s products are cleared by regulatory authorities; market
acceptance of PAVmed’s products once cleared and commercialized;
our ability to raise additional funding and other competitive
developments. PAVmed has not yet received clearance from the FDA or
other regulatory body to market many of its products. The Company
has been monitoring the COVID-19 pandemic and its impact on our
business. The Company expects the significance of the COVID-19
pandemic, including the extent of its effect on the Company’s
financial and operational results, to be dictated by, among other
things, the success of efforts to contain it and the impact of
actions taken in response. New risks and uncertainties may arise
from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. For a further list and
description of these and other important risks and uncertainties
that may affect PAVmed’s future operations, see Part I, Item IA,
“Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, as the same may
be updated in Part II, Item 1A, “Risk Factors” in any Quarterly
Report on Form 10-Q filed by PAVmed after its most recent Annual
Report. PAVmed disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
Contacts:
InvestorsMike HavrillaDirector of Investor Relations(814)
241-4138JMH@PAVmed.com
MediaShaun O’NeilChief Commercial Officer(518)
812-3087SMO@PAVmed.com
Katie GallagherLaVoieHealthScience(617)
792-3937PAVmed@lavoiehealthscience.com
###
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mai 2023 bis Mai 2024